Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of CORT125134 Phase 2 Formulation in Healthy Males
NCT06094712Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Apr 2016
- Primary completion
- Apr 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of relacorilant in Cushing's syndrome, sponsored by Corcept Therapeutics. Primary endpoints: Maximum concentration of plasma CORT125134 up to 120 hours, Time of maximum concentration of plasma CORT125134 up to 120 hours and 3 more. Started Apr 2016; status: completed.
02
Drugs
relacorilant
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT06094712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06094712.